On sickle cell, Q4 framed the pre-sNDA meeting as pending to define pathway, while Q1 updated to a specific action and timing: CEO Goff said Agios “plan [s] to submit an sNDA…in the second quarter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results